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To establish a rational molecular design for bisphosphonate (BP)-modified proteins for effi-
cient bone targeting, a pharmacokinetic study was performed using a series of alendronate
(ALN), a nitrogen-containing BP, modified proteins with various molecular weights and vary-
ing degrees of modification. Four proteins with different molecular weight—yeast glutathi-
one reductase (GR; MW: 112,000 Da), bovine serum albumin (BSA; MW: 67,000 Da),
recombinant human superoxide dismutase (SOD; MW: 32,000 Da), and chicken egg white
lysozyme (LZM; MW: 14,000 Da)—were modified with ALN to obtain ALN-modified pro-
teins. Pharmacokinetic analysis of the tissue distribution of the ALN-modified and unmodi-
fied proteins was performed after radiolabeling them with indium-111 (111In) by using a
bifunctional chelating agent. Calculation of tissue uptake clearances revealed that the bone
uptake clearances of 111In-ALN-modified proteins were proportional to the degree of ALN
modification. 111In-GR-ALN and BSA-ALN, the two high-molecular-weight proteins, effi-
ciently accumulated in bones, regardless of the degree of ALN modification. Approximately
36 and 34% of the dose, respectively, was calculated to be delivered to the bones. In con-
trast, the maximum amounts taken up by bone were 18 and 13% of the dose for 111In-SOD-
ALN(32) and LZM-ALN(9), respectively, because of their high renal clearance. 111In-SOD
modified with both polyethylene glycol (PEG) and ALN (111In-PEG-SOD-ALN) was effi-
ciently delivered to the bone. Approximately 36% of the dose was estimated to be delivered
to the bones. In an experimental bone metastasis mouse model, treatment with PEG-SOD-
ALN significantly reduced the number of tumor cells in the bone of the mice. These results
indicate that the combination of PEG and ALN modification is a promising approach for effi-
cient bone targeting of proteins with a high total-body clearance.
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Introduction
The prevalence of bone diseases is rapidly increasing as the population ages. Various endoge-
nous proteins, including enzymes and cytokines, represent new candidates as therapeutic
agents to treat bone diseases [1–4]. However, most protein drugs intended for bone diseases do
not have a high affinity for bone hydroxyapatite under physiological conditions, which limits
their therapeutic potential [1]. Therefore, targeting protein drugs to the bone is essential for
the treatment of bone diseases. Of the various strategies available, chemical modification is an
attractive approach for the targeted delivery of protein drugs, in terms of efficacy and safety,
because protein drugs have several functional groups that can be conjugated with ligands or
polymers [5].
To date, bone targeting of protein drugs by chemical modification has been studied with
several molecules, including tetracycline, acidic oligopeptides, and bisphosphonates (BPs) [6–
8]. BPs strongly inhibit the function of osteoclasts that mediate bone resorption, thereby
allowing for their use in the treatment of Paget’s disease, bone metastasis, hypercalcemia of
malignancy, and osteoporosis [9,10]. In addition, BPs are carbon-substituted pyrophosphate
analogs that exhibit a high affinity for hydroxylapatite. Consequently, BPs are rapidly distrib-
uted to the bone or excreted in the urine in equal proportion following intravenous injection
[11,12]. Accordingly, the modification of protein drugs with BPs could be useful for bone
targeting. It was reported that the bone accumulation of osteoprotegerin, a potent receptor acti-
vator of nuclear factor κB ligand (RANKL) inhibitor that prevents osteoclastogenesis, was
increased following BP modification [13]. Furthermore, bone metastasis was suppressed by
intravenous injection of BP-modified bovine catalase in mice [14]. Despite these promising
characteristics, there are no systemic studies on the application of BP modification to the bone
targeting of protein drugs with different physicochemical and biological characteristics. In fact,
the relationship between the physicochemical characteristics of proteins, such as the molecular
weight and degree of modification with BP, and their in vivo pharmacokinetic profiles are not
fully understood.
The aim of the present study was to establish a rational molecular design of BP-modified
proteins for efficient bone targeting in vivo. In this study, we used the nitrogen-containing BP,
alendronate (ALN) and conjugated it to various proteins to obtain ALN-modified proteins.
The bone targeting efficiency of ALN-modified proteins with various molecular weights and
degree of modification was examined after intravenous injection in mice, and pharmacokinetic
analyses were performed to obtain quantitative relationships between these two factors.
Materials and Methods
Animals
Male ddY mice (5-week-old) and female C57/BL6 mice (7-week-old) were purchased from
Japan SLC Inc. (Shizuoka, Japan), and were maintained under conventional housing condi-
tions. All animal experiments were conducted in accordance with the principles and proce-
dures outlined in the National Institutes of Health Guide for the Care and Use of Laboratory
Animals. The Animal Experimentation Committee of the Kyoto Pharmaceutical University
approved all protocols for animal experiments.
Chemicals
Glutathione reductase from yeast (GR, 1,000 U/mL) was purchased from Oriental Yeast,
Tokyo, Japan. Bovine serum albumin (BSA) was purchased from Sigma-Aldrich, St. Louis,
MO. Human recombinant superoxide dismutase solution (SOD, 300 or 450 U/μL) was
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purchased fromWako Pure Chemical Industries, Osaka, Japan. Lysozyme from chicken
egg whites (LZM,>9,000 U/mg) was purchased fromMP Biomedicals, Illkirch, France.
Alendronic acid, monosodium salt, trihydrate (ALN) was purchased from Toronto Research
Chemicals, Brisbane, North York, Canada. Methoxypolyethylene glycol N-succinimidyl
succinate (activated PEG; average molecular weight 5,200 Da) was purchased from NOF Co,
Tokyo, Japan. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDAC), diethylenetriamine-
pentaacetic acid (DTPA) anhydride and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES) were purchased from Dojindo Laboratory, Kumamoto, Japan. D-luciferin was pur-
chased from Promega, Madison, WI. Pharmalyte 3–10 and amberlyte IRN-150L were pur-
chased from GE Healthcare UK Ltd.,Buckinghamshire, UK.111Indium chloride ([111In]InCl3)
was supplied by Nihon Medi-Physic, Takarazuka, Japan. All other chemicals were obtained
commercially as reagent-grade products.
Synthesis and characterization of ALN-modified proteins
The ALN-modified proteins were synthesized by covalent attachment of ALN to the proteins.
GR (MW: 112,000 Da), BSA (MW: 67,000 Da), SOD (MW: 32,000 Da) and LZM (MW: 14,000
Da) were used as model proteins in this study. The coupling reaction of a protein with amine
of ALN by EDAC was performed according to a previously published method with slight mod-
ifications [15]. In brief, protein was added to the ALN dissolved in 0.1 M HEPES (pH 6.5) with
EDAC as a carboxyl activating agent. After incubation on ice for 1 h, a second aliquot of EDAC
was added to the solution, and the reaction mixture was stirred overnight at 4°C. The pH of the
reaction solution was adjusted to 6.5–7.0 during the first 2 h. The number of ALN residues per
protein molecule was controlled by the molar ratio of reagents, protein, ALN and EDAC. The
reaction mixture was applied to a column (Sephadex G-25 coarse, GE Healthcare, Little Chal-
font, UK) and fractions with larger molecular weights were collected. To remove protein aggre-
gates formed during the synthesis, reaction products were ultrafiltered through a membrane
(Vivaspin, GE Healthcare, Little Chalfont, UK) that traps and retains large protein aggregates.
Each derivative was then washed and concentrated by ultrafiltration against distilled water,
and lyophilized. These protein derivatives were subjected to SDS-PAGE analysis, and all were
found to produce one band (data not shown). To synthesize the polyethylene glycol-SOD-ALN
conjugate (PEG-SOD-ALN), SOD was mixed with activated PEG in borate buffer (pH 9.0) for
24 h at 4°C in the dark [16], and then mixed with ALN as described above. The number of
ALN conjugated to each derivative was determined by the molybdenum method [17]. The
number of PEG was estimated by the number of unreacted free amino groups, which was
determined by the trinitrobenzenesulfonic acid method [18]. The apparent molecular weight
of each derivative was estimated in reference to the number of ALN and PEG.
Isoelectric point of native proteins and ALN-modified proteins
The isoelectric point (pI) was measured by isoelectric focusing as reported previously [19]. The
gel consisted of acrylamide, bisacrylamide, glycerol, pharmalyte 3–10 for IEF, amberlyte IRN-
150L, TEMED, and ammonium persulfate. H2SO4 (0.1 M) and NaOH (0.1 M) were used as the
anolyte and catholyte, respectively. Samples were applied on the gel and subjected to electro-
phoresis at 500 V for 9 h, 600 V for 1 h and 800 V for 2 h. Aspergillus niger amyloglucosidase
(pI 3.5), Aspergillus niger glucose oxidase (pI 4.2), soybean trypsin inhibitor (pI 4.5), bovine
milk β-lactoglobulin (pI 5.3, 5.2), bovine erythrocytes carbonic anhydrase (pI 6.0), horse mus-
cle myoglobin (pI 6.9, 7.4), Lens culinaris lectin (pI 7.8, 8.0, 8.3), bovine pancreas ribonuclease
A (pI 9.5), and pig heart cytochrome C (pI 10.7) were used as pI markers.
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In vivo disposition experiment
Native proteins and ALN-modified proteins were radiolabeled with 111In using the bifunctional
chelating agent DTPA anhydride according to the method of Hnatowich et al., which was
described in a previous report [20,21]. In brief, DTPA-protein derivatives were synthesized in
0.1 M HEPES buffer (pH 7) and reacted with 111InCl3 to obtain
111In-labeled compound
in 0.1 M citrate buffer (pH 5.5). The reaction mixture was applied to a PD-10 column (GE
Healthcare, Little Chalfont, UK) and eluted with 0.1 M citrate buffer (pH 5.5). The derivative
fractions were collected and concentrated by ultrafiltration. Each 111In-labeled compound was
dissolved in saline, and the protein concentration was adjusted by the addition of non-radiola-
beled protein to the solution. The solution of 111In-protein was injected into the tail vein of
mice at a dose of 1 mg protein/kg. At the appropriate time after injection, blood was collected
from the vena cava under ether anesthesia, and the mice were then killed. Heparin sulfate was
used as an anticoagulant. Plasma was obtained from the blood by centrifugation at 5,000 g for
5 min. The liver, kidneys, spleen, heart, lungs, and bones of the lower extremity, i.e., tibiae and
femurs, were collected, rinsed with saline, and weighed; urine in the bladder was also collected.
The radioactivity in each sample was counted using an automatic gamma counter (1480 Wiz-
ard, Perkin-Elmer, Boston, MA, USA). The total wet bone weight was estimated as 12% of the
body weight, and the radioactivity in the bone was based on activity determined in tibiae and
femurs extrapolated to whole wet bone as reported previously [22].
Calculation of area under the plasma concentration-time curve (AUC)
and clearance
The 111In-radioactivity concentration in plasma was normalized with respect to the percentage
of the dose/ml and the time courses were analyzed using the nonlinear least-squares program
MULTI [23]. The tissue distribution profiles were evaluated using tissue uptake clearance
(CLtissue) according to the integration plot analysis. The amount in a tissue at time t (Xt) and
the area under the plasma concentration-time curve (AUC) from time 0 to t (AUC0-t) was nor-
malized with the plasma concentration at time t (Ct), and CLtissue was obtained from the slope
of the plot of Xt/Ct versus AUC0-t/Ct [24].
Effect of PEG-SOD-ALN on experimental bone metastasis
Experimental bone metastasis was induced by injecting 2 x 105 murine B16-BL6 cells labeled
with firefly luciferase gene (B16-BL6/Luc cells) [25] in 0.1 mL of RPMI into the left ventricle
of C57/BL6 mice. One and three days after tumor inoculation, saline, PEG-SOD or PEG-SOD-
ALN was injected into the lateral tail vein at a dose of 500 U/mouse. At 14 days after tumor
inoculation, mice were injected intraperitoneally with 2.5 mg D-luciferin, anesthetized with an
intraperitoneal injection of pentobarbital (50 mg/kg), and then imaging was performed using a
LAS-4000 (Fujifilm, Tokyo, Japan). Then, mice were killed, and the bones of lower limbs were
excised, and the luciferase activity in the tissue was measured in a luminometer (Lumat LB
9507, EG & G Berthold, Bad Wild-bad, Germany). The luciferase activity was converted to the
number of the tumor cells using a regression line, as reported previously [25].
Results
Physicochemical characteristics of ALN-modified proteins
Table 1 summarizes the physicochemical characteristics of the synthesized ALN-modified pro-
teins. The numbers of ALN molecules on the proteins ranged from 3 to 40. The number of
ALN-modified carboxyl groups depended on the amount of reacted ALN. PEG-SOD and
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PEG-SOD-ALN had an average of 10 PEG molecules per SOD molecule. The isoelectric points
of GR, BSA, and SOD were increased depending on the number of ALN residues, although the
apparent molecular weights were barely altered by ALN modification. Unfortunately, the iso-
electric points of LZM-ALN and PEG conjugates could not be determined, because of the out-
of-range and neutral isoelectric point of PEG, respectively.
Distribution of 111In-native proteins after intravenous administration
Figs 1–5 show the time course of the plasma concentrations and the cumulative amounts of
111In-radioactivity in major organs after intravenous injection of 111In-native- and ALN-modi-
fied proteins into mice. 111In-LZM and 111In-SOD quickly disappeared from plasma, whereas
the other proteins with high-molecular weights remained in the circulation for a longer period
of time (Figs 3 and 4). These results are in good agreement with previous studies [26–28]. The
amount of 111In-GR, 111In-BSA, 111In-SOD and 111In-LZM accumulated in bone were 9.1, 2.1,
0.3, and 2.2% of the initial dose 3 h after injection, respectively (Figs 1–4). Approximately 77
and 92% of 111In-radioactivity accumulated in the kidney 3 h after injection of 111In- SOD and
LZM, respectively (Figs 3 and 4), whereas those of 111In-GR and 111In-BSA were less than 2%
(Figs 1 and 2). Other tissues exhibited no significant radioactivity after injection of all 111In-
native proteins.
Table 1. Physicochemical characteristics of ALN-modified proteins.










GR 0 0 - 112,000 4.5
GR-ALN(4) 3.79 1.11 - 113,000 8
GR-ALN(17) 17.3 5.06 - 117,000 8.3
BSA 0 0 - 67,000 4.8
BSA-ALN (3) 2.47 2.52 - 67,800 4.8
BSA-ALN (28) 27.7 28.3 - 74,600 9.5–10.7
BSA-ALN (40) 39.7 40.5 - 77,900 >10.7
SOD 0 0 - 32,000 4.9
SOD-ALN(3) 2.99 7.88 - 32,800 4.9
SOD-ALN(32) 31.6 83.2 - 40,700 10.7
PEG(10)-SOD 0 0 9.62 82,000 N.D.
PEG(10)-
SOD-ALN(4)
3.79 10 9.62 83,100 N.D.
LZM 0 0 - 14,000 11.2
LZM-ALN(5) 29.9 29.9 - 15,400 N.D.
LZM-ALN(9) 49.4 49.4 - 16,400 N.D.
a) The alendronate (ALN) content was determined by the molybdenum method using ALN as a standard. The number of ALN residues was calculated
using the molar ratio of ALN residues attached to the protein.
b)The number of PEG was estimated by the number of unreacted free amino groups, which was determined by the trinitrobenzenesulfonic acid method.
c) The molecular weight of each protein derivative was estimated by considering of the number of ALN residues and PEG modiﬁcations.
N.D.; not determined
doi:10.1371/journal.pone.0135966.t001
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Distribution of 111In-ALN-modified proteins after intravenous administration
111In-ALN-modified proteins were taken up by the bone in various amounts, according to
the degree of modification (Figs 1–5). Fig 6 summarizes the bone accumulation of 111In-ALN-
modified proteins as a function of the number of ALN residues. The maximum amount taken
up by the bone was 36, 34, 18, and 13% of the dose for 111In-GR-ALN(4),111In-BSA-ALN(3),
111In-SOD-ALN(32) and 111In-LZM-ALN(9), respectively (Figs 1–6). Although the bone
accumulation of 111In-GR-ALN and 111In-BSA-ALN was greatly increased with a low degree
of modification, the increase in the number of attached ALN residues accelerated accumulation
Fig 1. Time-courses of the plasma concentration, and bone, liver, kidney, and lung accumulation of 111In-labeled GR derivatives in mice after
intravenous injection at a dose of 1 mg protein/kg. The total wet bone weight was estimated as 12% of the body weight, and the radioactivity in the bone
was based on activity determined in tibiae and femurs extrapolated to whole wet bone as reported previously [22]. Results are expressed as the mean ± S.D.
of three mice. ●: GR, : GR-ALN (4), ▼: GR-ALN (17).
doi:10.1371/journal.pone.0135966.g001
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in the liver, kidney, and lung, and reduced bone accumulation (Figs 1, 2 and 6). 111In-SOD-
ALN and 111In-LZM-ALN accumulated in the bone depending on the number of ALN resi-
dues. However, 111In-radioactivity after intravenous injection of 111In-SOD-ALN and
111In-LZM-ALN was observed mainly in the kidney or liver (Figs 3 and 4 and 6). In contrast,
111In-PEG-SOD-ALN and 111In-PEG-SOD slowly disappeared from the plasma and accumu-
lated in the bone. Approximately 36 and 8.4% of the dose were recovered in the bone 24 h after
injection, respectively (Figs 5 and 6). Little radioactivity was counted in any other tissues for all
ALN-modified proteins.
Calculation of pharmacokinetic parameters
To quantitatively compare the distribution profiles of the 111In-native proteins and 111In-ALN-
modified proteins, CLtotal, CLtissue, and AUC were calculated based on the distribution data
(Table 2). 111In-GR and BSA had large AUCs and low total clearances, reflecting the high
plasma retention after intravenous injection. The AUCs of 111In- SOD and 111In-LZM were
much lower than those of 111In-GR and BSA, but increased depending on the molecular weight.
The CLtotal of native proteins were almost inversely correspondent with their AUC. The CLbone
of 111In-GR, 111In-BSA, 111In-SOD and 111In-LZMwere 0.04, 0.02, 0.10, and 1.39 ml/h, respec-
tively, which were quite low compared with their CLtotal.
Fig 2. Time-courses of the plasma concentration, and bone, liver, kidney, and lung accumulation of
111In-labeled BSA derivatives in mice after intravenous injection at a dose of 1 mg protein/kg. The total
wet bone weight was estimated as 12% of the body weight, and the radioactivity in the bone was based on
activity determined in tibiae and femurs extrapolated to whole wet bone as reported previously [22].Results
are expressed as the mean ± S.D. of three mice. ●: BSA, : BSA-ALN (3), ▼: BSA-ALN (28),5: BSA-ALN
(40).
doi:10.1371/journal.pone.0135966.g002
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ALNmodification increased the CLbone of all the proteins, without significantly changing the
tissue uptake clearance in any other organ, except for the liver, kidneys, and lungs. The maximum
CLbone of
111In-GR-ALN, 111In-BSA-ALN, 111In-SOD-ALN, and 111In-LZM-ALN were 1.37, 6.73,
6.26, and 2.55 ml/hr, respectively, which were much higher than those of native protein. The CLto-
tal of
111In-ALN-modified proteins were proportional to the degree of modification, and CLliver,
CLrenal, or CLlung accounted for most of the CLtotal in proteins with a high degree of modification.
Among the series of SOD derivatives, PEG-SOD had the highest AUC. The AUC of 111In-
PEG-SOD-ALN was much higher than that of 111In-SOD-ALN and 111In-SOD. Additionally,
the CLliver and CLkidney of
111In-PEG-SOD-ALN were much lower than those of 111In-SOD-
ALN and 111In-SOD. In addition, 111In-PEG-SOD-ALN showed the highest CLbone among the
SOD derivatives. The uptake rate in the bone of 111In-PEG-SOD-ALN was 94-fold greater than
that of 111In-SOD.
Inhibition of bone metastasis of melanoma cells by PEG-SOD-ALN
Fig 7A shows the number of B16–BL6/Luc cells in the tibiae and femurs of the bone metastasis
mouse model. Treatment with PEG-SOD-ALN significantly reduced the number of tumor
cells in the bone of the mice. In marked contrast, PEG-SOD had no statistically significant
effects on the number of tumor cells in the bones.
Fig 3. Time-courses of the plasma concentration, and bone, liver, kidney, and lung accumulation of
111In-labeled SOD derivatives in mice after intravenous injection at a dose of 1 mg protein/kg. The total
wet bone weight was estimated as 12% of the body weight, and the radioactivity in the bone was based on
activity determined in tibiae and femurs extrapolated to whole wet bone as reported previously [22].Results
are expressed as the mean ± S.D. of three mice. ●: SOD, : SOD-ALN (3), ▼: SOD-ALN (32).
doi:10.1371/journal.pone.0135966.g003
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Fig 7B shows the macroscopic observation of B16–BL6/Luc cells in the tibiae and femurs of
the bone metastasis mouse model. PEG-SOD-ALN effectively suppressed the metastatic colo-
nies in the tibiae and femurs of the bone metastasis mouse model. S1 Fig shows the in vivo
imaging on the distribution of the tumor cells in live mice monitored by the luciferase activity.
Similarly, the growth of metastatic tumor cells was effectively inhibited by PEG-SOD-ALN.
These data strongly supported the quantitative results.
Statistical analysis
Statistical comparisons with the vehicle control group were performed using Dunnett's test at a
significance level of p< 0.05.
Discussion
To establish a rational molecular design for BP-modified proteins to efficiently target the
bone in vivo, we performed a systemic pharmacokinetic study using a series of ALN-modified
proteins with various molecular weights and degrees of modification. The pharmacokinetic
study showed that the bone uptake clearance of ALN-modified proteins was closely related to
the degree of ALN modification. In a preliminary experiment, we examined the stability of
Fig 4. Time-courses of the plasma concentration, and bone, liver, kidney, and lung accumulation of
111In-labeled LZM derivatives in mice after intravenous injection at a dose of 1 mg protein/kg. The total
wet bone weight was estimated as 12% of the body weight, and the radioactivity in the bone was based on
activity determined in tibiae and femurs extrapolated to whole wet bone as reported previously [22].Results
are expressed as the mean ± S.D. of three mice. ●: LZM, : LZM-ALN (5), ▼: LZM-ALN (9).
doi:10.1371/journal.pone.0135966.g004
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BSA-ALN(3) in mouse plasma by measuring free ALN using HPLC. No free ALN was detected
in the sample 3 h after incubation at 37°C (data not shown), indicating that the linkage of ALN
with proteins was stable in plasma. Therefore, the high bone uptake clearance of ALN-modified
proteins could be explained by the high affinity of ALN to hydroxylapatite, the major compo-
nent of bone [6–8,11,12]. However, ALN modification did not change the high renal clearance
of SOD and LZM, the two low-molecular weight proteins, and hardly increased the bone accu-
mulation compared with GR and BSA, the high-molecular weight proteins with long blood
circulation. These results suggest that the affinity of ALN to bone is not sufficient for the effec-
tive bone targeting of proteins with high total-body clearance. The greater bone distribution
of PEG-SOD-ALN could be the consequence of reduced renal clearance, affording a greater
opportunity to interact with bone, because it was reported that PEG modification increases
the plasma retention of proteins in vivo [16, 29, 30]. Although there was a concern that the
interaction of ALN of the ALN-modified proteins with bone could be sterically prevented by
the bulky PEG molecules [13], the pharmacokinetic analysis in the present study indicates that
PEG modification barely reduces the affinity of SOD-ALN to bone. Thus, the combination of
PEG and ALN modification is a promising approach for efficient bone targeting of proteins
with high total-body clearance.
The bone accumulation of GR-ALN and BSA-ALN, the two high-molecular weight pro-
teins, was almost inversely correlated with the number of ALN residues. In general, the electric
Fig 5. Time-courses of the plasma concentration, and bone, liver, kidney, and lung accumulation of
111In-labeled PEG-SOD derivatives in mice after intravenous injection at a dose of 1 mg protein/kg.
The total wet bone weight was estimated as 12% of the body weight, and the radioactivity in the bone was
based on activity determined in tibiae and femurs extrapolated to whole wet bone as reported previously [22].
Results are expressed as the mean ± S.D. of three mice. ●: SOD, : PEG(10)-SOD, ▼: PEG(10)-SOD-ALN
(4).
doi:10.1371/journal.pone.0135966.g005
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Fig 6. Effect of the number of ALN residues on bone accumulation of 111In-labeled ALN-modified
proteins. 111In-labeled ALN-modified proteins were intravenously administered into mice at a dose of 1 mg
protein/kg. The total wet bone weight was estimated as 12% of the body weight, and the radioactivity in the
bone was based on activity determined in tibiae and femurs extrapolated to whole wet bone as reported
previously [22]. Results are expressed as the mean ± S.D. of three mice. ●: GR-ALN, ▲: BSA-ALN, □:
SOD-ALN, : LZM-ALN,4: PEG-SOD-ALN.
doi:10.1371/journal.pone.0135966.g006
Table 2. AUC and clearance of 111In-labeled ALN-modified proteins in mice after intravenous injection of 1 mg protein/kg.
Compound AUC(h•% of dose/ml) CLtotal (ml/h) CLbone (ml/h) CLliver (ml/h) CLkidney (ml/h) CLlung (ml/h) CLurine (ml/h)
GR 545 0.18 0.04 0.02 0.01 0.002 0.003
GR-ALN(4) 130 0.77 0.37 0.22 0.04 0.006 0.02
GR-ALN(17) 1.91 52.4 1.37 35.8 1.87 1.37 0.38
BSA 259 0.39 0.02 0.03 0.01 0.003 0.004
BSA-ALN (3) 265 0.38 0.12 0.03 0.02 0.002 0.03
BSA-ALN (28) 1.86 53.8 2.21 32.6 2.17 3.19 0.41
BSA-ALN (40) 0.81 124 6.73 62.8 2.62 18 2.14
SOD 9.64 10.4 0.1 0.02 8.43 0.02 3.28
SOD-ALN(3) 6.49 15.4 1.51 0.45 11.8 0.02 0.75
SOD-ALN(32) 2.32 43.1 6.26 14.7 7.65 0.36 6.85
PEG(10)-SOD 207 0.48 0.12 0.03 0.02 0.002 0.002
PEG(10)-SOD-ALN(4) 30.8 3.25 0.94 0.11 0.38 0.01 0.06
LZM 4.18 24 1.39 0.65 9.5 0.38 2.99
LZM-ALN(5) 3.48 28.7 2.55 3.06 12.1 0.59 2.43
LZM-ALN(9) 3.5 28.6 2.35 1.76 13.1 0.35 2.54
doi:10.1371/journal.pone.0135966.t002
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charge of proteins also plays an important role in the tissue distribution of protein derivatives
[5, 31–33]. It was reported that cationic proteins, such as amidated proteins, are rapidly accu-
mulated in the liver after intravenous injection [32,33]. In the present study, ALN modification
increased the positive charge depending on the number of ALN residues, likely due to the fact
that the carboxyl residues of the proteins are modified. These results suggest that the greater
hepatic distribution of GR-ALN and BSA-ALN with large number of ALN moieties is due to
the electrostatic interaction between the negatively charged cell surface and the increased
positive charge of GR and BSA [32, 33]. Furthermore, it was also reported that high concentra-
tions of BPs form insoluble complexes with calcium or insoluble aggregates in the blood [34].
Therefore, the large number of ALN residues on GR-ALN and BSA-ALN may also enhance
the aggregation of GR-ALN or BSA-ALN in the blood through interactions with calcium
in the blood, thereby enhancing uptake by the reticuloendothelial system in the liver and accu-
mulation in the pulmonary capillary. These two effects could be interrelated in the tissue
Fig 7. Effect of SOD derivatives on the growth of metastatic tumor cells in the bones of lower limbs
after its administrations 1 and 3 days after tumor injection. (A) Number of B16BL6/Luc cells in the bones
of lower limb of mice administered with PEG-SOD or PEG-SOD-ALN. Mice were sacrificed at 14 days after
tumor inoculation. Results are expressed as the mean ± SD of 5–6 mice. *, a statistically significant
difference compared with the saline group (P < 0.05). (B) Macroscopic observation of bone metastasis in the
mouse lower limb at 14 days after inoculation of B16BL6/Luc cells (2×105 cells/mouse) into the mouse left
ventricle. (a) Saline, (b) PEG-SOD, (c) PEG-SOD-ALN.
doi:10.1371/journal.pone.0135966.g007
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distribution, affecting the fate of GR-ALN and BSA-ALN with a large number of ALNmoieties.
Although the calculation of bone uptake clearance revealed that the affinity of ALN-modified
proteins to bone was proportional to the degree of modification, the results of the tissue distri-
bution suggest that approximately 3–4 ALN/protein is the optimal degree of modification for
bone targeting of these proteins.
It was reported that bones possess a membrane consisting of lining cells, which function
as a marrow-blood barrier. Thus, the accessibility of exogenous large substances to the bone
surface is extremely limited [7, 35]. In contrast, it was also reported that exogenous macromol-
ecules, which are approximately 60 nm in diameter, accumulated within myeloid bone marrow
interstitial space [36]. Thus, there have been several controversies concerning the vascular
permeability of bone marrow. In the present study, ALN-modified proteins showed high bone
uptake clearance (0.12–6.73 ml/h) compared with unmodified proteins (0.02–1.39 ml/h).
Previous studies reported that the bone plasma flow rate was approximately 10.2 ml/h for a
22 g mouse [37]. These results indicate that the bone uptake of proteins is not limited by the
marrow-blood barrier. In bone metastasis, where tumor cells cause vascular endothelial cell
junctions to loosen and increase vascular permeability [38], the transport of ALN-modified
proteins through the marrow-blood barrier would be considered relatively easy. In addition, it
was reported that BPs have a high affinity to hydroxyapatite at areas of increased bone turn-
over, such as bone metastasis [12].
The inhibitory effects on bone metastasis treated with PEG-SOD-ALN may be associated
with these results, together with those on pharmacokinetics studies in the present study.
Because reactive oxygen species (ROS) play important roles in a series of steps of tumor metas-
tasis and the tumor metastasis is effectively prevented by targeting of ROS scavenging SOD
and catalase [39], the inhibitory effect on bone metastasis treated with PEG-SOD-ALN could
be explained by efficient ROS elimination in the bone. Although further studies are needed to
elucidate the detailed mechanism underlying this inhibition, these results suggest that our bone
targeting strategy using BP is a promising approach for the treatment of bone metastasis.
Conclusions
The efficient bone targeting of GR and BSA, two high-molecular weight proteins with long
blood circulation, was successfully achieved by ALN modification; however, decreased bone
distribution was observed with a high degree of modification. These results indicate that
approximately 3–4 ALN/protein is an optimal degree of modification for bone targeting of pro-
teins. In contrast, low-molecular-weight proteins, such as SOD and LZM with a high total-
body clearance, need both modification with 3–4 ALN/protein and PEG for efficient delivery
to bone. Thus, the present study has provided useful basic information for therapeutic strate-
gies and the molecular design of BP-modified proteins for use as therapeutic agents and drug
carriers for bone targeting in vivo.
Supporting Information
S1 Fig. Effect of SOD derivatives on the growth of metastatic tumor cells in the bones of
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expression in the lower limb at 14 days after inoculation. (a) Saline, (b) PEG-SOD, (c) PEG-
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